ID   PI4KB_HUMAN             Reviewed;         816 AA.
AC   Q9UBF8; B4DGI2; O15096; P78405; Q5VWB9; Q5VWC0; Q5VWC1; Q9BWR6;
DT   14-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   28-JUN-2023, entry version 195.
DE   RecName: Full=Phosphatidylinositol 4-kinase beta {ECO:0000305};
DE            Short=PI4K-beta;
DE            Short=PI4Kbeta;
DE            Short=PtdIns 4-kinase beta;
DE            EC=2.7.1.67 {ECO:0000269|PubMed:11277933, ECO:0000269|PubMed:9405935};
DE   AltName: Full=NPIK;
DE   AltName: Full=PI4K92;
DE   AltName: Full=PI4KIII {ECO:0000303|PubMed:22124328, ECO:0000303|PubMed:22258260};
GN   Name=PI4KB {ECO:0000312|HGNC:HGNC:8984}; Synonyms=PIK4CB;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:AAC51156.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=9405935; DOI=10.1093/dnares/4.4.273;
RA   Suzuki K., Hirano H., Okutomi K., Suzuki M., Kuga Y., Fujiwara T.,
RA   Kanemoto N., Isono K., Horie M.;
RT   "Identification and characterization of a novel human phosphatidylinositol
RT   4-kinase.";
RL   DNA Res. 4:273-280(1997).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain {ECO:0000312|EMBL:BAA21661.1};
RX   PubMed=9405938; DOI=10.1093/dnares/4.4.301;
RA   Saito T., Seki N., Ishii H., Ohira M., Hayashi A., Kozuma S., Hori T.-A.;
RT   "Complementary DNA cloning and chromosomal mapping of a novel
RT   phosphatidylinositol kinase gene.";
RL   DNA Res. 4:301-305(1997).
RN   [3] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), ACTIVITY REGULATION, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Heart {ECO:0000269|PubMed:9020160};
RX   PubMed=9020160; DOI=10.1074/jbc.272.7.4384;
RA   Meyers R., Cantley L.C.;
RT   "Cloning and characterization of a wortmannin-sensitive human
RT   phosphatidylinositol 4-kinase.";
RL   J. Biol. Chem. 272:4384-4390(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain {ECO:0000312|EMBL:AAH00029.1}, and Testis
RC   {ECO:0000312|EMBL:AAH40300.1};
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   PROTEIN SEQUENCE OF 2-118; 121-229; 236-303; 319-442; 497-798 AND 804-816
RP   (ISOFORM 2), CLEAVAGE OF INITIATOR METHIONINE, ACETYLATION AT GLY-2,
RP   PHOSPHORYLATION AT SER-294, INTERACTION WITH ACBD3; ARMH3; RAB11B; YWHAB;
RP   YWHAE; YWHAG; YWHAH; YWHAQ; YWHAZ AND SFN, MUTAGENESIS OF 40-LEU--VAL-42;
RP   43-ILE--PRO-45; 46-GLU-VAL-47; 49-GLN-LYS-50; CYS-52; 53-GLN-GLU-54;
RP   55-VAL-LEU-56 AND 57-GLU--VAL-59, AND MASS SPECTROMETRY.
RX   PubMed=23572552; DOI=10.1128/mbio.00098-13;
RA   Greninger A.L., Knudsen G.M., Betegon M., Burlingame A.L., DeRisi J.L.;
RT   "ACBD3 interaction with TBC1 domain 22 protein is differentially affected
RT   by enteroviral and kobuviral 3A protein binding.";
RL   MBio 4:E00098-E00098(2013).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=9148941; DOI=10.1074/jbc.272.20.13236;
RA   Wong K., Meyers R., Cantley L.C.;
RT   "Subcellular locations of phosphatidylinositol 4-kinase isoforms.";
RL   J. Biol. Chem. 272:13236-13241(1997).
RN   [10]
RP   FUNCTION.
RX   PubMed=10559940; DOI=10.1038/12993;
RA   Godi A., Pertile P., Meyers R., Marra P., Di Tullio G., Iurisci C.,
RA   Luini A., Corda D., De Matteis M.A.;
RT   "ARF mediates recruitment of PtdIns-4-OH kinase-beta and stimulates
RT   synthesis of PtdIns(4,5)P2 on the Golgi complex.";
RL   Nat. Cell Biol. 1:280-287(1999).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, ACTIVITY
RP   REGULATION, COFACTOR, AND PHOSPHORYLATION AT SER-258; THR-263; SER-266;
RP   SER-277; SER-294; THR-438; SER-511 AND THR-519.
RX   PubMed=11277933; DOI=10.1046/j.1432-1327.2001.02089.x;
RA   Suer S., Sickmann A., Meyer H.E., Herberg F.W., Heilmeyer L.M.G. Jr.;
RT   "Human phosphatidylinositol 4-kinase isoform PI4K92. Expression of the
RT   recombinant enzyme and determination of multiple phosphorylation sites.";
RL   Eur. J. Biochem. 268:2099-2106(2001).
RN   [12]
RP   FUNCTION.
RX   PubMed=12749687; DOI=10.1002/tbmb.718540873;
RA   Heilmeyer L.M.G. Jr., Vereb G. Jr., Vereb G., Kakuk A., Szivak I.;
RT   "Mammalian phosphatidylinositol 4-kinases.";
RL   IUBMB Life 55:59-65(2003).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-428, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [14]
RP   INTERACTION WITH ARF1 AND ARF3, AND SUBCELLULAR LOCATION.
RX   PubMed=17555535; DOI=10.1111/j.1600-0854.2007.00594.x;
RA   Haynes L.P., Sherwood M.W., Dolman N.J., Burgoyne R.D.;
RT   "Specificity, promiscuity and localization of ARF protein interactions with
RT   NCS-1 and phosphatidylinositol-4 kinase-III beta.";
RL   Traffic 8:1080-1092(2007).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-511, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-258; SER-277; SER-428 AND
RP   SER-511, PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-294 (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-428, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-258; SER-266 AND SER-428, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-428, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   FUNCTION (MICROBIAL INFECTION), SUBCELLULAR LOCATION, IDENTIFICATION IN A
RP   COMPLEX AICHI VIRUS PROTEIN 3A/ACBD3/PI4KB (MICROBIAL INFECTION), AND
RP   INTERACTION WITH ACBD3.
RX   PubMed=22124328; DOI=10.1038/emboj.2011.429;
RA   Sasaki J., Ishikawa K., Arita M., Taniguchi K.;
RT   "ACBD3-mediated recruitment of PI4KB to picornavirus RNA replication
RT   sites.";
RL   EMBO J. 31:754-766(2012).
RN   [22]
RP   FUNCTION (MICROBIAL INFECTION).
RX   PubMed=22253445; DOI=10.1074/jbc.m111.312561;
RA   Yang N., Ma P., Lang J., Zhang Y., Deng J., Ju X., Zhang G., Jiang C.;
RT   "Phosphatidylinositol 4-kinase IIIbeta is required for severe acute
RT   respiratory syndrome coronavirus spike-mediated cell entry.";
RL   J. Biol. Chem. 287:8457-8467(2012).
RN   [23]
RP   FUNCTION (MICROBIAL INFECTION), INTERACTION WITH AICHI VIRUS PROTEIN 3A
RP   (MICROBIAL INFECTION), IDENTIFICATION IN A COMPLEX AICHI VIRUS PROTEIN
RP   3A/ACBD3/PI4KB (MICROBIAL INFECTION), AND INTERACTION WITH ACBD3.
RX   PubMed=22258260; DOI=10.1128/jvi.06778-11;
RA   Greninger A.L., Knudsen G.M., Betegon M., Burlingame A.L., Derisi J.L.;
RT   "The 3A protein from multiple picornaviruses utilizes the golgi adaptor
RT   protein ACBD3 to recruit PI4KIIIbeta.";
RL   J. Virol. 86:3605-3616(2012).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-258; SER-266; SER-277;
RP   SER-428; SER-511 AND THR-517, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   SUBCELLULAR LOCATION, AND ACTIVITY REGULATION (MICROBIAL INFECTION).
RX   PubMed=24672044; DOI=10.1128/jvi.00208-14;
RA   Ishikawa-Sasaki K., Sasaki J., Taniguchi K.;
RT   "A complex comprising phosphatidylinositol 4-kinase IIIbeta, ACBD3, and
RT   Aichi virus proteins enhances phosphatidylinositol 4-phosphate synthesis
RT   and is critical for formation of the viral replication complex.";
RL   J. Virol. 88:6586-6598(2014).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   INTERACTION WITH GGA2, AND SUBCELLULAR LOCATION.
RX   PubMed=28289207; DOI=10.1073/pnas.1615163114;
RA   Daboussi L., Costaguta G., Ghukasyan R., Payne G.S.;
RT   "Conserved role for Gga proteins in phosphatidylinositol 4-kinase
RT   localization to the trans-Golgi network.";
RL   Proc. Natl. Acad. Sci. U.S.A. 114:3433-3438(2017).
RN   [28]
RP   INTERACTION WITH ACBD3, MUTAGENESIS OF ILE-43 AND ASP-44, FUNCTION
RP   (MICROBIAL INFECTION), IDENTIFICATION IN A COMPLEX PROTEIN 3A/ACBD3/PI4KB
RP   (MICROBIAL INFECTION), AND ACTIVITY REGULATION (MICROBIAL INFECTION).
RX   PubMed=27989622; DOI=10.1016/j.str.2016.11.016;
RA   McPhail J.A., Ottosen E.H., Jenkins M.L., Burke J.E.;
RT   "The molecular basis of Aichi virus 3A protein activation of
RT   phosphatidylinositol 4 kinase IIIbeta, PI4KB, through ACBD3.";
RL   Structure 25:121-131(2017).
RN   [29]
RP   INTERACTION WITH ATG9A.
RX   PubMed=30917996; DOI=10.1083/jcb.201901115;
RA   Judith D., Jefferies H.B.J., Boeing S., Frith D., Snijders A.P.,
RA   Tooze S.A.;
RT   "ATG9A shapes the forming autophagosome through Arfaptin 2 and
RT   phosphatidylinositol 4-kinase IIIbeta.";
RL   J. Cell Biol. 218:1634-1652(2019).
RN   [30]
RP   STRUCTURE BY NMR OF 1-68 IN COMPLEX WITH ACBD3, INTERACTION WITH ACBD3, AND
RP   MUTAGENESIS OF VAL-42; ILE-43; VAL-47; VAL-55 AND LEU-56.
RX   PubMed=27009356; DOI=10.1038/srep23641;
RA   Klima M., Toth D.J., Hexnerova R., Baumlova A., Chalupska D., Tykvart J.,
RA   Rezabkova L., Sengupta N., Man P., Dubankova A., Humpolickova J.,
RA   Nencka R., Veverka V., Balla T., Boura E.;
RT   "Structural insights and in vitro reconstitution of membrane targeting and
RT   activation of human PI4KB by the ACBD3 protein.";
RL   Sci. Rep. 6:23641-23641(2016).
CC   -!- FUNCTION: Phosphorylates phosphatidylinositol (PI) in the first
CC       committed step in the production of the second messenger
CC       inositol-1,4,5,-trisphosphate (PIP). May regulate Golgi
CC       disintegration/reorganization during mitosis, possibly via its
CC       phosphorylation. Involved in Golgi-to-plasma membrane trafficking (By
CC       similarity). {ECO:0000250|UniProtKB:O08561,
CC       ECO:0000269|PubMed:10559940, ECO:0000269|PubMed:11277933,
CC       ECO:0000269|PubMed:12749687, ECO:0000269|PubMed:9405935}.
CC   -!- FUNCTION: (Microbial infection) Plays an essential role in Aichi virus
CC       RNA replication (PubMed:22124328, PubMed:27989622, PubMed:22258260).
CC       Recruited by ACBD3 at the viral replication sites (PubMed:22124328,
CC       PubMed:27989622). {ECO:0000269|PubMed:22124328,
CC       ECO:0000269|PubMed:22258260, ECO:0000269|PubMed:27989622}.
CC   -!- FUNCTION: (Microbial infection) Required for cellular spike-mediated
CC       entry of human coronavirus SARS-CoV. {ECO:0000269|PubMed:22253445}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + ATP = a
CC         1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-phosphate) + ADP +
CC         H(+); Xref=Rhea:RHEA:19877, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:57880, ChEBI:CHEBI:58178, ChEBI:CHEBI:456216;
CC         EC=2.7.1.67; Evidence={ECO:0000269|PubMed:11277933,
CC         ECO:0000269|PubMed:9405935};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19878;
CC         Evidence={ECO:0000305|PubMed:11277933};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:11277933};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:11277933};
CC   -!- ACTIVITY REGULATION: Inhibited by wortmannin and adenosine
CC       (PubMed:11277933). Increased kinase activity upon interaction with
CC       NCS1/FREQ (By similarity). {ECO:0000250|UniProtKB:O02810,
CC       ECO:0000269|PubMed:11277933}.
CC   -!- ACTIVITY REGULATION: (Microbial infection) Activated by Aichi virus
CC       protein 3A, this activation is sensitized by ACBD3.
CC       {ECO:0000269|PubMed:24672044, ECO:0000269|PubMed:27989622}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=1 mM for PtdIns {ECO:0000269|PubMed:11277933};
CC         KM=1 mM for ATP {ECO:0000269|PubMed:11277933};
CC   -!- SUBUNIT: Interacts with ARF1 and ARF3 in the Golgi complex, but not
CC       with ARF4, ARF5 or ARF6 (PubMed:17555535). Interacts with NCS1/FREQ in
CC       a calcium-independent manner. Interacts with CALN1/CABP8 and
CC       CALN2/CABP7; in a calcium-dependent manner; this interaction competes
CC       with NCS1/FREQ binding (By similarity). Interacts with ACBD3
CC       (PubMed:23572552, PubMed:27009356, PubMed:27989622, PubMed:22124328,
CC       PubMed:22258260). Interacts with ARMH3, YWHAB, YWHAE, YWHAG, YWHAH,
CC       YWHAQ, YWHAZ and SFN (PubMed:23572552). Interacts with GGA2 (via VHS
CC       domain); the interaction is important for PI4KB location at the Golgi
CC       apparatus membrane (PubMed:28289207). Interacts with ATG9A
CC       (PubMed:30917996). {ECO:0000250|UniProtKB:O08561,
CC       ECO:0000269|PubMed:17555535, ECO:0000269|PubMed:22124328,
CC       ECO:0000269|PubMed:22258260, ECO:0000269|PubMed:23572552,
CC       ECO:0000269|PubMed:27009356, ECO:0000269|PubMed:27989622,
CC       ECO:0000269|PubMed:28289207, ECO:0000269|PubMed:30917996}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with Aichi virus protein 3A.
CC       Part of a complex Aichi virus protein 3A/ACBD3/PI4KB that allows the
CC       synthesis of PI4P at the viral RNA replication sites.
CC       {ECO:0000269|PubMed:22124328, ECO:0000269|PubMed:22258260,
CC       ECO:0000269|PubMed:27989622}.
CC   -!- INTERACTION:
CC       Q9UBF8; Q9H3P7: ACBD3; NbExp=4; IntAct=EBI-1053214, EBI-1791792;
CC       Q9UBF8; P03495: NS; Xeno; NbExp=2; IntAct=EBI-1053214, EBI-2548993;
CC       Q9UBF8; PRO_0000424692 [P03300]; Xeno; NbExp=9; IntAct=EBI-1053214, EBI-21242141;
CC       Q9UBF8-2; P62491: RAB11A; NbExp=5; IntAct=EBI-16107849, EBI-745098;
CC   -!- SUBCELLULAR LOCATION: Endomembrane system. Mitochondrion outer
CC       membrane; Peripheral membrane protein. Rough endoplasmic reticulum
CC       membrane; Peripheral membrane protein. Golgi apparatus
CC       {ECO:0000269|PubMed:22124328}. Golgi apparatus membrane
CC       {ECO:0000269|PubMed:24672044, ECO:0000269|PubMed:27009356,
CC       ECO:0000269|PubMed:28289207}. Cytoplasm, perinuclear region. Note=Found
CC       in the outer membrane of mitochondria and membranes of the rough
CC       endoplasmic reticulum. Recruited to the Golgi complex by the small
CC       GTPase ARF to stimulate the synthesis of phosphatidylinositol 4,5-
CC       bisphosphate (PIP2) on the Golgi complex. Recruited to the Golgi
CC       apparatus membrane by ACBD3 (PubMed:24672044, PubMed:27009356,
CC       PubMed:28289207). GGA2 is also involved in the recruitment
CC       (PubMed:28289207). {ECO:0000269|PubMed:24672044,
CC       ECO:0000269|PubMed:27009356, ECO:0000269|PubMed:28289207}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1 {ECO:0000269|PubMed:9405935}; Synonyms=NPIK-B
CC       {ECO:0000269|PubMed:9405935};
CC         IsoId=Q9UBF8-1; Sequence=Displayed;
CC       Name=2 {ECO:0000269|PubMed:9405935}; Synonyms=NPIK-C
CC       {ECO:0000269|PubMed:9405935};
CC         IsoId=Q9UBF8-2; Sequence=VSP_050627;
CC       Name=3;
CC         IsoId=Q9UBF8-3; Sequence=VSP_037133;
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest levels in heart,
CC       skeletal muscle, pancreas, testis and ovary. Weakly expressed in liver.
CC       {ECO:0000269|PubMed:9020160, ECO:0000269|PubMed:9405935,
CC       ECO:0000269|PubMed:9405938}.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. Type III PI4K
CC       subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA21661.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC       Sequence=EAW53450.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AJ011121; CAA09495.1; -; mRNA.
DR   EMBL; AJ011122; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; AJ011123; CAA09496.1; -; mRNA.
DR   EMBL; AB005910; BAA21661.1; ALT_INIT; mRNA.
DR   EMBL; U81802; AAC51156.1; -; mRNA.
DR   EMBL; AK294606; BAG57793.1; -; mRNA.
DR   EMBL; AL391069; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471121; EAW53449.1; -; Genomic_DNA.
DR   EMBL; CH471121; EAW53450.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; BC000029; AAH00029.1; -; mRNA.
DR   EMBL; BC040300; AAH40300.1; -; mRNA.
DR   CCDS; CCDS55637.1; -. [Q9UBF8-3]
DR   CCDS; CCDS55638.1; -. [Q9UBF8-2]
DR   CCDS; CCDS81376.1; -. [Q9UBF8-1]
DR   PIR; JC5706; JC5706.
DR   RefSeq; NP_001185702.1; NM_001198773.2. [Q9UBF8-2]
DR   RefSeq; NP_001185703.1; NM_001198774.1. [Q9UBF8-2]
DR   RefSeq; NP_001185704.1; NM_001198775.2. [Q9UBF8-3]
DR   RefSeq; NP_001317650.1; NM_001330721.1. [Q9UBF8-1]
DR   RefSeq; NP_002642.1; NM_002651.3.
DR   RefSeq; XP_016856979.1; XM_017001490.1.
DR   RefSeq; XP_016856980.1; XM_017001491.1.
DR   RefSeq; XP_016856981.1; XM_017001492.1.
DR   PDB; 2N73; NMR; -; B=1-68.
DR   PDB; 4D0L; X-ray; 2.94 A; A/C/E=121-799.
DR   PDB; 4D0M; X-ray; 6.00 A; A/C/G/I/M/O/Q/S/W/Y/c/g=121-799.
DR   PDB; 4WAE; X-ray; 3.32 A; A=128-799.
DR   PDB; 4WAG; X-ray; 3.41 A; A=128-799.
DR   PDB; 5C46; X-ray; 2.65 A; E=121-799.
DR   PDB; 5C4G; X-ray; 3.20 A; E=121-799.
DR   PDB; 5EUQ; X-ray; 3.20 A; E=121-248, E=523-799.
DR   PDB; 5FBL; X-ray; 3.37 A; A=128-799.
DR   PDB; 5FBQ; X-ray; 3.79 A; A=128-799.
DR   PDB; 5FBR; X-ray; 3.28 A; A=128-799.
DR   PDB; 5FBV; X-ray; 3.29 A; A=128-799.
DR   PDB; 5FBW; X-ray; 3.49 A; A=128-799.
DR   PDB; 5LX2; X-ray; 2.58 A; B=292-297.
DR   PDB; 5NAS; X-ray; 2.08 A; C/D=289-297.
DR   PDB; 6GL3; X-ray; 2.77 A; A/B=317-428, A/B=532-798.
DR   PDBsum; 2N73; -.
DR   PDBsum; 4D0L; -.
DR   PDBsum; 4D0M; -.
DR   PDBsum; 4WAE; -.
DR   PDBsum; 4WAG; -.
DR   PDBsum; 5C46; -.
DR   PDBsum; 5C4G; -.
DR   PDBsum; 5EUQ; -.
DR   PDBsum; 5FBL; -.
DR   PDBsum; 5FBQ; -.
DR   PDBsum; 5FBR; -.
DR   PDBsum; 5FBV; -.
DR   PDBsum; 5FBW; -.
DR   PDBsum; 5LX2; -.
DR   PDBsum; 5NAS; -.
DR   PDBsum; 6GL3; -.
DR   AlphaFoldDB; Q9UBF8; -.
DR   SMR; Q9UBF8; -.
DR   BioGRID; 111316; 56.
DR   DIP; DIP-42267N; -.
DR   IntAct; Q9UBF8; 27.
DR   MINT; Q9UBF8; -.
DR   STRING; 9606.ENSP00000357869; -.
DR   BindingDB; Q9UBF8; -.
DR   ChEMBL; CHEMBL3268; -.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugCentral; Q9UBF8; -.
DR   GuidetoPHARMACOLOGY; 2149; -.
DR   SwissLipids; SLP:000001947; -. [Q9UBF8-2]
DR   GlyGen; Q9UBF8; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9UBF8; -.
DR   PhosphoSitePlus; Q9UBF8; -.
DR   BioMuta; PI4KB; -.
DR   DMDM; 38372507; -.
DR   CPTAC; CPTAC-2965; -.
DR   CPTAC; CPTAC-2966; -.
DR   EPD; Q9UBF8; -.
DR   jPOST; Q9UBF8; -.
DR   MassIVE; Q9UBF8; -.
DR   MaxQB; Q9UBF8; -.
DR   PaxDb; Q9UBF8; -.
DR   PeptideAtlas; Q9UBF8; -.
DR   ProteomicsDB; 83959; -. [Q9UBF8-1]
DR   ProteomicsDB; 83960; -. [Q9UBF8-2]
DR   ProteomicsDB; 83961; -. [Q9UBF8-3]
DR   Antibodypedia; 1666; 154 antibodies from 30 providers.
DR   DNASU; 5298; -.
DR   Ensembl; ENST00000368872.5; ENSP00000357866.1; ENSG00000143393.17. [Q9UBF8-2]
DR   Ensembl; ENST00000368873.6; ENSP00000357867.1; ENSG00000143393.17. [Q9UBF8-1]
DR   Ensembl; ENST00000368874.8; ENSP00000357868.4; ENSG00000143393.17. [Q9UBF8-2]
DR   Ensembl; ENST00000529142.5; ENSP00000433149.1; ENSG00000143393.17. [Q9UBF8-3]
DR   GeneID; 5298; -.
DR   KEGG; hsa:5298; -.
DR   MANE-Select; ENST00000368873.6; ENSP00000357867.1; NM_001369623.2; NP_001356552.1.
DR   UCSC; uc001ext.4; human. [Q9UBF8-1]
DR   AGR; HGNC:8984; -.
DR   CTD; 5298; -.
DR   DisGeNET; 5298; -.
DR   GeneCards; PI4KB; -.
DR   HGNC; HGNC:8984; PI4KB.
DR   HPA; ENSG00000143393; Low tissue specificity.
DR   MIM; 602758; gene.
DR   neXtProt; NX_Q9UBF8; -.
DR   OpenTargets; ENSG00000143393; -.
DR   PharmGKB; PA162399420; -.
DR   VEuPathDB; HostDB:ENSG00000143393; -.
DR   eggNOG; KOG0903; Eukaryota.
DR   GeneTree; ENSGT00550000074892; -.
DR   InParanoid; Q9UBF8; -.
DR   OMA; GNKMFSF; -.
DR   OrthoDB; 147843at2759; -.
DR   PhylomeDB; Q9UBF8; -.
DR   TreeFam; TF102042; -.
DR   BioCyc; MetaCyc:HS07046-MON; -.
DR   BRENDA; 2.7.1.67; 2681.
DR   PathwayCommons; Q9UBF8; -.
DR   Reactome; R-HSA-1660514; Synthesis of PIPs at the Golgi membrane.
DR   SignaLink; Q9UBF8; -.
DR   SIGNOR; Q9UBF8; -.
DR   BioGRID-ORCS; 5298; 200 hits in 1169 CRISPR screens.
DR   ChiTaRS; PI4KB; human.
DR   GeneWiki; PI4KB; -.
DR   GenomeRNAi; 5298; -.
DR   Pharos; Q9UBF8; Tchem.
DR   PRO; PR:Q9UBF8; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; Q9UBF8; protein.
DR   Bgee; ENSG00000143393; Expressed in right lobe of thyroid gland and 206 other tissues.
DR   ExpressionAtlas; Q9UBF8; baseline and differential.
DR   Genevisible; Q9UBF8; HS.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005768; C:endosome; TAS:ProtInc.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:MGI.
DR   GO; GO:0000139; C:Golgi membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IBA:GO_Central.
DR   GO; GO:0005741; C:mitochondrial outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0030867; C:rough endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0004430; F:1-phosphatidylinositol 4-kinase activity; IDA:UniProtKB.
DR   GO; GO:0071889; F:14-3-3 protein binding; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0007040; P:lysosome organization; IDA:MGI.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:Reactome.
DR   GO; GO:0046854; P:phosphatidylinositol phosphate biosynthetic process; IBA:GO_Central.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IBA:GO_Central.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; TAS:ProtInc.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   CDD; cd22246; PI4KB_NTD; 1.
DR   CDD; cd05168; PI4Kc_III_beta; 1.
DR   Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR036940; PI3/4_kinase_cat_sf.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR001263; PI3K_accessory_dom.
DR   InterPro; IPR015433; PI_Kinase.
DR   PANTHER; PTHR10048:SF22; PHOSPHATIDYLINOSITOL 4-KINASE BETA; 1.
DR   PANTHER; PTHR10048; PHOSPHATIDYLINOSITOL KINASE; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
DR   PROSITE; PS51545; PIK_HELICAL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Cytoplasm;
KW   Direct protein sequencing; Endoplasmic reticulum; Golgi apparatus;
KW   Host-virus interaction; Kinase; Lipid metabolism; Membrane; Mitochondrion;
KW   Mitochondrion outer membrane; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:23572552"
FT   CHAIN           2..816
FT                   /note="Phosphatidylinositol 4-kinase beta"
FT                   /id="PRO_0000088829"
FT   DOMAIN          29..242
FT                   /note="PIK helical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00878"
FT   DOMAIN          535..801
FT                   /note="PI3K/PI4K catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          1..30
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          41..67
FT                   /note="Interaction with ACBD3"
FT                   /evidence="ECO:0000269|PubMed:27009356,
FT                   ECO:0000269|PubMed:27989622, ECO:0000305|PubMed:23572552"
FT   REGION          101..120
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          248..318
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          541..547
FT                   /note="G-loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          668..676
FT                   /note="Catalytic loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          687..711
FT                   /note="Activation loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   COMPBIAS        277..294
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         2
FT                   /note="N-acetylglycine"
FT                   /evidence="ECO:0000269|PubMed:23572552"
FT   MOD_RES         258
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11277933,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         263
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:11277933"
FT   MOD_RES         266
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11277933,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         275
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BKC8"
FT   MOD_RES         277
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11277933,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163"
FT   MOD_RES         284
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8BKC8"
FT   MOD_RES         294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11277933,
FT                   ECO:0000269|PubMed:23572552"
FT   MOD_RES         428
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         438
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:11277933"
FT   MOD_RES         511
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:11277933,
FT                   ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         517
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         519
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000269|PubMed:11277933"
FT   VAR_SEQ         1..332
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_037133"
FT   VAR_SEQ         304..318
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9020160, ECO:0000303|PubMed:9405935"
FT                   /id="VSP_050627"
FT   MUTAGEN         40..42
FT                   /note="LSV->AAA: Small decrease in C10ORF76-binding. No
FT                   effect on ACBD3-, nor RAB11B-binding."
FT                   /evidence="ECO:0000269|PubMed:23572552"
FT   MUTAGEN         42
FT                   /note="V->A: No loss of interaction with ACBD3."
FT                   /evidence="ECO:0000269|PubMed:27009356"
FT   MUTAGEN         43..45
FT                   /note="IDP->AAA: Drastically decreased ACBD3-binding. No
FT                   effect on C10ORF76-, nor RAB11B-binding."
FT                   /evidence="ECO:0000269|PubMed:23572552"
FT   MUTAGEN         43
FT                   /note="I->A: Loss of interaction with ACBD3."
FT                   /evidence="ECO:0000269|PubMed:27009356,
FT                   ECO:0000269|PubMed:27989622"
FT   MUTAGEN         44
FT                   /note="D->A: Loss of interaction with ACBD3."
FT                   /evidence="ECO:0000269|PubMed:27989622"
FT   MUTAGEN         46..47
FT                   /note="EV->AA: No effect on ACBD3-, C10ORF76-, nor
FT                   RAB11B-binding."
FT                   /evidence="ECO:0000269|PubMed:23572552"
FT   MUTAGEN         47
FT                   /note="V->A: No loss of interaction with ACBD3."
FT                   /evidence="ECO:0000269|PubMed:27009356"
FT   MUTAGEN         49..50
FT                   /note="QK->AA: No effect on ACBD3-, C10ORF76-, nor
FT                   RAB11B-binding."
FT                   /evidence="ECO:0000269|PubMed:23572552"
FT   MUTAGEN         52
FT                   /note="C->A: No effect on ACBD3-, C10ORF76-, nor
FT                   RAB11B-binding."
FT                   /evidence="ECO:0000269|PubMed:23572552"
FT   MUTAGEN         53..54
FT                   /note="QE->AA: Drastically decreased C10ORF76- and
FT                   RAB11B-binding. 6-fold increase in ACBD3-binding."
FT                   /evidence="ECO:0000269|PubMed:23572552"
FT   MUTAGEN         55..56
FT                   /note="VL->AA: Drastically decreased ACBD3-binding. No
FT                   effect on C10ORF76-, nor RAB11B-binding."
FT                   /evidence="ECO:0000269|PubMed:23572552"
FT   MUTAGEN         55
FT                   /note="V->A: Loss of interaction with ACBD3."
FT                   /evidence="ECO:0000269|PubMed:27009356"
FT   MUTAGEN         56
FT                   /note="L->A: Loss of interaction with ACBD3."
FT                   /evidence="ECO:0000269|PubMed:27009356"
FT   MUTAGEN         57..59
FT                   /note="EKV->AAA: No effect on ACBD3-, C10ORF76-, nor
FT                   RAB11B-binding."
FT                   /evidence="ECO:0000269|PubMed:23572552"
FT   CONFLICT        216
FT                   /note="L -> V (in Ref. 3; AAC51156)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        339
FT                   /note="L -> V (in Ref. 3; AAC51156)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        340
FT                   /note="A -> V (in Ref. 3; AAC51156)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        370
FT                   /note="P -> S (in Ref. 3; AAC51156)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        446
FT                   /note="F -> S (in Ref. 4; BAG57793)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        754
FT                   /note="M -> L (in Ref. 4; BAG57793)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        796
FT                   /note="S -> G (in Ref. 4; BAG57793)"
FT                   /evidence="ECO:0000305"
FT   HELIX           45..63
FT                   /evidence="ECO:0007829|PDB:2N73"
FT   HELIX           129..134
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           141..150
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           154..163
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           164..166
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           169..173
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           176..185
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           188..204
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           206..218
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           234..242
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   TURN            319..322
FT                   /evidence="ECO:0007829|PDB:4WAE"
FT   HELIX           323..338
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           339..341
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          342..344
FT                   /evidence="ECO:0007829|PDB:6GL3"
FT   HELIX           345..356
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   TURN            357..359
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           360..362
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          364..366
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          372..374
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          376..380
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           383..385
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          392..394
FT                   /evidence="ECO:0007829|PDB:6GL3"
FT   STRAND          397..405
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   TURN            409..411
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           537..546
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   TURN            549..552
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          556..564
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           570..588
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          600..602
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          604..606
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          608..610
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          614..618
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           619..625
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           630..637
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           644..667
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   TURN            674..676
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          677..680
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          685..687
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           712..717
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          721..723
FT                   /evidence="ECO:0007829|PDB:6GL3"
FT   HELIX           724..741
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           744..755
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   HELIX           761..763
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          765..767
FT                   /evidence="ECO:0007829|PDB:5FBR"
FT   HELIX           768..774
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   STRAND          778..780
FT                   /evidence="ECO:0007829|PDB:6GL3"
FT   HELIX           782..796
FT                   /evidence="ECO:0007829|PDB:5C46"
FT   MOD_RES         Q9UBF8-2:294
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
SQ   SEQUENCE   816 AA;  91379 MW;  CAD8791729BB4308 CRC64;
     MGDTVVEPAP LKPTSEPTSG PPGNNGGSLL SVITEGVGEL SVIDPEVAQK ACQEVLEKVK
     LLHGGVAVSS RGTPLELVNG DGVDSEIRCL DDPPAQIREE EDEMGAAVAS GTAKGARRRR
     QNNSAKQSWL LRLFESKLFD ISMAISYLYN SKEPGVQAYI GNRLFCFRNE DVDFYLPQLL
     NMYIHMDEDV GDAIKPYIVH RCRQSINFSL QCALLLGAYS SDMHISTQRH SRGTKLRKLI
     LSDELKPAHR KRELPSLSPA PDTGLSPSKR THQRSKSDAT ASISLSSNLK RTASNPKVEN
     EDEELSSSTE SIDNSFSSPV RLAPEREFIK SLMAIGKRLA TLPTKEQKTQ RLISELSLLN
     HKLPARVWLP TAGFDHHVVR VPHTQAVVLN SKDKAPYLIY VEVLECENFD TTSVPARIPE
     NRIRSTRSVE NLPECGITHE QRAGSFSTVP NYDNDDEAWS VDDIGELQVE LPEVHTNSCD
     NISQFSVDSI TSQESKEPVF IAAGDIRRRL SEQLAHTPTA FKRDPEDPSA VALKEPWQEK
     VRRIREGSPY GHLPNWRLLS VIVKCGDDLR QELLAFQVLK QLQSIWEQER VPLWIKPYKI
     LVISADSGMI EPVVNAVSIH QVKKQSQLSL LDYFLQEHGS YTTEAFLSAQ RNFVQSCAGY
     CLVCYLLQVK DRHNGNILLD AEGHIIHIDF GFILSSSPRN LGFETSAFKL TTEFVDVMGG
     LDGDMFNYYK MLMLQGLIAA RKHMDKVVQI VEIMQQGSQL PCFHGSSTIR NLKERFHMSM
     TEEQLQLLVE QMVDGSMRSI TTKLYDGFQY LTNGIM
//
